Skip to main content
Premium Trial:

Request an Annual Quote

Biosite Partners with Neurocrine Biosciences in Antibody, Stroke Target Collaboration

NEW YORK, Feb. 20 - Biosite and Neurocrine Biosciences have signed a three-year research collaboration, the companies said today.


Under the agreement, Neurocrine will provide drug targets, and Biosite will use its phage display technology to generate antibodies to the targets. Biosite will get fees for antibodies when it delivers them to Neurocrine, as well as possible milestone fees, and diagnostic licenses to stroke targets to which Neurocrine has rights. Neurocrine will use the antibodies in its drug discovery research.


Biosite, which focuses on protein-based diagnostics, also has an antibody discovery collaboration agreement with Ciphergen and an agreement to developing protein chips with Large Scale Biology.


For more information on this collaboration, see the company statement.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.